The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Subscribe To Our Newsletter & Stay Updated